Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Facial Rosacea Clear all
Completed Phase 3 Interventional Results available

An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

NCT03352323
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
Oxymetazoline
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

NCT02120924
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid, Vehicle, Finacea
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Fremont, California • Santa Monica, California • Brandon, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689
View directory record Official record
Conditions
Bioequivalence
Interventions
Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355458
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Clinton Township, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01174030
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Hot Springs, Arkansas • San Francisco, California • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face

NCT02800148
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid foam, Azelaic acid foam - Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

NCT05278624
View directory record Official record
Conditions
Rosacea
Interventions
Roflumilast Cream
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional

4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness

NCT03841032
View directory record Official record
Conditions
Rosacea
Interventions
Coppertone, BAY1183345
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea

NCT01618864
View directory record Official record
Conditions
Rosacea, Wrinkles
Interventions
Luxe
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
21 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

NCT06952517
View directory record Official record
Conditions
Papular-pustular Rosacea, Papulopustular Rosacea (PPR), Papulopustular Rosacea
Interventions
Clascoterone Cream 1%
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Not applicable Interventional

Rosacea Radiofrequency Microneedling

NCT06801717
View directory record Official record
Conditions
Rosacea, Papulopustular, Rosacea, Erythematotelangiectatic
Interventions
KTP Laser Therapy, Radiofrequency microneedling
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

NCT03954444
View directory record Official record
Conditions
Rosacea
Interventions
Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355471
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 Gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Hot Springs, Arkansas • Miami Beach, Florida • Newnan, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

NCT03689010
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

NCT02289352
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine, placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Hot Springs, Arkansas • Long Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 4 Interventional

Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

NCT00436527
View directory record Official record
Conditions
Rosacea
Interventions
Metronidazole gel 1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional

Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device

NCT05592548
View directory record Official record
Conditions
Rosacea, Papulopustular
Interventions
cold atmospheric plasma
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea

NCT04106726
View directory record Official record
Conditions
Facial Rosacea
Interventions
Soolantra® Ivermectin cream 1%, Ivermectin cream 1%, Placebo for Ivermectin cream 1%
Drug
Lead sponsor
Zydus Worldwide DMCC
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Brandon, Florida • Fort Lauderdale, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01318733
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel 0.5%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Santa Monica, California • Denver, Colorado • Longmont, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

NCT02268474
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Interventions
532nm KTP Laser vs 595nm Pulse Dye Laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

NCT04508205
View directory record Official record
Conditions
Rosacea
Interventions
CGB-400
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Fremont, California • San Diego, California • Edgewater, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

NCT00697541
View directory record Official record
Conditions
Erythematous Rosacea
Interventions
0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 12:02 PM EDT